Survival differences with immediate versus delayed chemotherapy for asymptomatic incurable metastatic colorectal cancer.

CONCLUSIONS: Based on a limited number of trials, very sparse data, and uncertainty of the evidence, this review was unable to establish whether there was a difference in overall survival or other clinically relevant outcomes, between immediate or delayed chemotherapy in persons with metastatic, incurable, colorectal cancer. The results should be interpreted with caution. PMID: 30480771 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Tags: Cochrane Database Syst Rev Source Type: research

Related Links:

Premalatha Pushpanathan, Gifty Sara Mathew, Sribal Selvarajan, Krishna G Seshadri, Padma SrikanthIndian Journal of Medical Microbiology 2019 37(2):268-277 Gut microbiota are microorganisms that inhabit the gut; they coexist peacefully with the host, thereby contributing to the health and well-being of individuals. Bacteroidetes and Firmicutes largely dominate the gut microbial flora. The intestinal flora promotes intestinal mucosal integrity, provides essential nutrients such as vitamins and enzymes, protects the body against pathogens and produces antimicrobial peptides such as defensins, C-type lectins, cathelicidins, t...
Source: Indian Journal of Medical Microbiology - Category: Microbiology Authors: Source Type: research
CONCLUSION: A significant association was observed between DPYD*9A polymorphism and CAPOX induced dose-limiting toxicities strengthening its role as a predictive biomarker. PMID: 31653159 [PubMed - in process]
Source: Asian Pacific Journal of Cancer Prevention - Category: Cancer & Oncology Tags: Asian Pac J Cancer Prev Source Type: research
ConclusionsCet every two weeks in combination with FOLFIRI or alternating FOLFIRI/FOLFOX is well tolerated with high RR and long OS. We recommend FOLFIRI + cet every 2 weeks in patients with RAS and BRAFwt mCRC.Clinical trial identification2011-004188-65.Legal entity responsible for the studyNordic Biomodulation Group.FundingMerck.DisclosureC. Kersten: Research grant / Funding (institution), Licensing / Royalties, Relationship is unrelated to this study: Merck KGaA. All other authors have declared no conflicts of interest.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsAtezo + bev + cobi had an acceptable safety profile with manageable AEs with improved activity over that reported with SOC in 2L+ mCRC. A greater benefit trend was seen in pts with a RAS mutation vs wild-type tumours. Table:603P2L therapy (n  = 25)3L+ therapy (n = 24)Overall (N = 49)Confirmed response per RECIST 1.1, n (%)a2 (8%)2 (8%)4 (8%)mPFS (range), moa5.5 (3.6-9.4)5.8(2.4-9.0)5.5 (3.6-7.5)mOS (range), moNE(11.7-NE)11.8 (8.7-21.8)11.8 (9.0-21.8)RAS mutant (n  = 33)RAS wild-type/ unknown (n = 16)Pb HR (95% CI)DCR, n (%)c (95% CI)12 (36) (2...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
AbstractBackgroundThe orally administered combination trifluridine and tipiracil hydrochloride (TAS-102) has been approved as third line treatment in metastatic colorectal cancer, demonstrating survival benefit and acceptable toxicity profile in the phase III RECOURSE study.MethodsWe performed an updated multicentre retrospective observational study of patients with metastatic colorectal cancer, receiving TAS-102 as third line treatment between 2016 and 2019 in 8 cancer centers across the UK. Medical records were reviewed for clinicopathological characteristics, treatment, survival and toxicity outcomes. Prognostic and pre...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
Conditions:   Colon Adenocarcinoma;   Diarrhea Interventions:   Drug: Antibiotics;   Drug: Bile Acid Binder Sponsors:   University of Aarhus;   Danish Cancer Society Recruiting
Source: - Category: Research Source Type: clinical trials
Dongyan Zhang1†, Hui Liu1†, Sixin Wang1, Wei Zhang1, Jing Wang1, Hongwu Tian2, Yamin Wang1 and Haifeng Ji1* 1Institute of Animal Husbandry and Veterinary Medicine, Beijing Academy of Agriculture and Forestry Sciences, Beijing, China 2Beijing Research Center of Intelligent Equipment for Agriculture, Beijing, China Lactobacillus has a positive effect on the host intestinal microbiota. In piglets, dietary supplementation with Lactobacillus affects general health and plays an important role in nutrient digestion and fermentation. However, this association requires further investigation. Here, we studie...
Source: Frontiers in Microbiology - Category: Microbiology Source Type: research
Publication date: Available online 11 April 2019Source: Inorganica Chimica ActaAuthor(s): Irene S. Um, Evangeline Armstrong-Gordon, Yvonne E. Moussa, Danijela Gnjidic, Nial J. WheateAbstractA cross-sectional descriptive study in Australia was undertaken to examine the current clinical guidelines on the use of platinum-based drugs in cancer treatment. From the Australian EviQ system, data from each chemotherapy protocol was collected with respect to recommended drugs for specific cancer types, drug doses, and dose modifications. Only three drugs have marketing approval: cisplatin, carboplatin, and oxaliplatin, and they are ...
Source: Inorganica Chimica Acta - Category: Chemistry Source Type: research
Purpose of review Chronic diarrhoea remains a diagnostic challenge, with numerous causes and few effective symptomatic treatments. This review focuses on new methods for diagnosis of common disorders and alerts readers to rarer causes through a systematic approach to the underlying mechanisms. Recent findings New strategies are emerging to stratify the need for endoscopic investigation. Faecal immunochemical testing, combined with standard blood tests, shows promise in excluding colorectal cancers, adenoma and inflammatory bowel disease, challenging the current use of faecal calprotectin. Serum analysis for markers of...
Source: Current Opinion in Gastroenterology - Category: Gastroenterology Tags: SMALL INTESTINE: Edited by Reena Sidhu Source Type: research
We describe the overall safety and tolerability profiles based on a literature review of all published phase I and II clinical trials in this setting. Drug exposure, tumour mutational status and metastases resectability are discussed. A review of pubmed and abstracts of major oncology congresses from 2009 to 2018, with MeSH and full-text search terms for clinical trials of anti-EGFR for "metastatic" or "advanced" "colorectal cancer/adenocarcinoma" was implemented. Only English language publications were included. Expert opinion: Efficacy data from phase II trials are promising, but the safety ...
Source: Expert Opinion on Investigational Drugs - Category: Drugs & Pharmacology Tags: Expert Opin Investig Drugs Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Colorectal Cancer | Databases & Libraries | Diarrhoea | General Medicine | International Medicine & Public Health | Palliative | Study | Toxicology | WHO